Primary Uterine Cervix Melanoma Resembling Malignant Peripheral Nerve Sheath Tumor: A Case Report

Sara Pusceddu(Fondazione IRCCS Istituto Nazionale dei Tumori), Antonino Ditto(Fondazione IRCCS Istituto Nazionale dei Tumori), Emilio Bajetta(Fondazione Lanza), Marco Platania(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Luisa Carcangiu(Fondazione IRCCS Istituto Nazionale dei Tumori), Roberto Buzzoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori)
International Journal of Gynecological Pathology
September 16, 2008
10.1097/pgp.0b013e31817323c4
Cited by 18

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780